Noah Stansfield

1 week ago | cgtlive.com | Noah Stansfield

Fate Therapeutics’ FT819, an investigational allogeneic induced pluripotent stem cell (iPSC)-derived chimeric antigen receptor T-cell (CAR-T) therapy, has garnered regenerative medicine advanced therapy (RMAT) designation from the FDA for active moderate to severe systemic lupus erythematosus (SLE), including lupus nephritis (LN).1 FT819, the development of which is supported by a California Institute of Regenerative Medicine grant that provides $7.9 million in funding, is currently being...

1 week ago | cgtlive.com | Renier J Brentjens |Noah Stansfield

April 14, 2025By Renier Brentjens, MD, PhD, the chair of the department of medicine at Roswell Park Comprehensive Cancer Center, discussed the innovations necessary to make CAR-T therapy effective in solid tumor indications. One of the ongoing challenges in oncology cell therapy is applying chimeric antigen receptor T-cell (CAR-T) therapy, which has proven efficacious in blood cancers, to solid tumors. One of the methods currently being explored for this purpose is armored CAR T-cells.

1 week ago | cgtlive.com | Noah Stansfield

Welcome to CGTLive®’s Weekly Rewind! We’ve compiled 5 highlights from this week’s coverage of advances in gene and cell therapies, including FDA actions, notable research, and interviews with experts across the field. The designations apply to lupus, myositis, and scleroderma indications. The chair of the department of medicine at Roswell Park Comprehensive Cancer Center discussed the innovations necessary to make CAR-T therapy effective in solid tumor indications.

1 week ago | cgtlive.com | Noah Stansfield

April 11, 2025In observance of World Parkinson's Day, held annually on April 11, we took a look back at the past year's news in cell and gene therapy for PD. According to the Michael J. Fox Foundation, almost 1 million people in United States live with Parkinson disease (PD) and more than 6 million people in the world live with PD. Notably, the symptoms of PD and their severity vary widely, and can be different for every person.

2 weeks ago | cgtlive.com | Noah Stansfield

Lexeo Therapeutics’ LX2006, an adeno-associated virus (AAV) vector-based gene therapy, has demonstrated the ability to reduce left ventricular mass index (LVMI) in patients with Friedreich ataxia (FA) cardiomyopathy who had a normal LVMI at baseline.1The data come from patients treated across 2 studies: the Lexeo phase 1/2 SUNRISE-FA clinical trial (NCT05445323) and the phase 1a Weill Cornell Medicine investigator-initiated trial (NCT05302271).